Caprion Buys PPD's Biomarker Business | GenomeWeb

NEW YORK (GenomeWeb News) – Caprion Proteomics said today that it has acquired the biomarker services division of PPD, a contract research firm focused on pharmaceutical services based in Wilmington, NC, for an undisclosed sum.

Montreal-based Caprion said that it closed the acquisition of PPD Biomarker Discovery Services on December 31, 2009.

Caprion said that it will fulfill PPD’s existing contractual biomarker obligations from its Montreal facilities and from a new US facility to be called Caprion Proteomics, US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.